Pharvaris (PHVS) Earnings Date & Reports

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PHVS is expected to report earnings to fall 6.30% to -72 cents per share on April 24

Q4'24

Est.

$-0.72

Q3'24

Missed

by $0.18

Q2'24

Est.

$-0.55

Q1'24

Beat

by $0.04

Q4'23

Missed

by $0.21

The last earnings report on November 13 showed earnings per share of -76 cents, missing the estimate of -59 cents. With 75.12K shares outstanding, the current market capitalization sits at 810.78M.

View a ticker or compare two or three

Compare

PHVS